ArticleCancers2020

Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia.

Claudia Tandler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.